Kura Oncology KURA Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$278.67M-60.2% | -$173.98M-14.0% | -$152.63M-12.4% | -$135.84M-4.1% | ||
| $1.03M+21.7% | $848K-0.1% | $849K+11.9% | $759K+36.0% | ||
| $37.11M+9.5% | $33.9M+20.7% | $28.08M+6.7% | $26.32M+11.6% | ||
| $515K-1.5% | $523K+9.6% | $477K+553% | $73K-81.7% | ||
| —— | $2.06M— | $0— | —— | ||
| $413K— | $0— | $0— | —— | ||
| —— | -$1.63M— | —— | -$802K— | ||
| —— | $16.83M+49.6% | $11.25M— | —— | ||
| —— | $6.85M— | —— | $2.94M— | ||
| $1.04M+37.6% | $758K+453% | $137K— | —— | ||
| $206.55M-25.8% | $278.18M— | $0— | —— | ||
| —— | —— | —— | —— | ||
| —— | $134.32M+208% | -$124.82M-13.4% | -$110.06M-5.3% | ||
| $6.64M+1,306% | $472K+181% | $168K-73.2% | $626K-45.4% | ||
| $761.59M+15.6% | $659.05M+60.8% | $409.82M+51.4% | $270.66M— | ||
| $755.13M+35.3% | $557.93M+31.1% | $425.55M+40.0% | $303.91M— | ||
| —— | —— | $15.56M— | —— | ||
| $1.79M-79.2% | $8.6M— | —— | $24.72M+459% | ||
| —— | —— | —— | $575K— | ||
| $1.79M-98.8% | $154.42M— | —— | $38.57M— | ||
| —— | $187.14M— | —— | —— | ||
| $8.49M-35.4% | $13.14M+39.5% | $9.42M— | —— | ||
| $515K-1.5% | $523K+9.6% | $477K+553% | $73K-81.7% | ||
| $1.03M+21.7% | $848K-0.1% | $849K+11.9% | $759K+36.0% | ||
| —— | $16.83M+49.6% | $11.25M— | —— | ||
| —— | —— | —— | —— | ||
| $6.36M— | —— | $685K+220% | -$571K-274% | ||
| $1.04M+37.6% | $758K+453% | $137K— | —— | ||
| —— | $6.85M— | —— | —— | ||
| $761.59M+15.6% | $659.05M+60.8% | $409.82M+51.4% | $270.66M— | ||
| $755.13M+35.3% | $557.93M+31.1% | $425.55M+40.0% | $303.91M— | ||
| $1.79M-79.2% | $8.6M— | —— | $4.42M— | ||
| $206.55M-25.8% | $278.18M— | $0— | —— | ||
| —— | —— | —— | —— | ||
| —— | $133.85M+207% | -$124.99M-12.9% | -$110.69M-4.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kura Oncology generate?
- Kura Oncology (KURA) generated -$267.2M in operating cash flow over the trailing twelve months.
- What is Kura Oncology's free cash flow?
- After $6.5M of capital expenditures, Kura Oncology's free cash flow was -$271.6M over the trailing twelve months, down 302.9% year over year.
- Where does Kura Oncology's cash flow data come from?
- Every line is extracted from Kura Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
